Testicle

Internationally Recognized Urologist, Robotic Surgeon and Researcher Dr. Andrew J. Stephenson Joins Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partners

Retrieved on: 
Monday, December 18, 2023

is pleased to announce that Andrew J. Stephenson, MD, MBA, FACS, FRCS(C) has joined its care team .

Key Points: 
  • is pleased to announce that Andrew J. Stephenson, MD, MBA, FACS, FRCS(C) has joined its care team .
  • Dr. Stephenson has performed more than 2,000 robotic urology surgeries in his career.
  • Associated Medical Professionals of NY is a leading multi-specialty practice spanning 19 locations in Central New York, including ten offices and nine hospitals.
  • Christopher M. Pieczonka, MD, Chief Executive Officer of Associated Medical Professionals of NY and Corporate Director of Clinical Research of U.S. Urology Partners , stated, “A.M.P.

YourChoice Therapeutics begins first-in-human trial for male birth control pill

Retrieved on: 
Wednesday, December 13, 2023

YourChoice Therapeutics, Inc., a pioneer of hormone-free family planning products, began dosing male volunteers in a phase one clinical study of YCT-529, a drug candidate designed to offer the first hormone-free male birth control pill.

Key Points: 
  • YourChoice Therapeutics, Inc., a pioneer of hormone-free family planning products, began dosing male volunteers in a phase one clinical study of YCT-529, a drug candidate designed to offer the first hormone-free male birth control pill.
  • While a male birth control pill has been a vision for decades, current drug candidates in clinical development use hormonal agents that suppress testosterone to prevent sperm production.
  • We thank our investors and the male volunteers who have stepped forward to be a part of this mission.”
    The Male Contraceptive Initiative has contributed generous funding to the development of the first hormone-free male birth control pill since its inception.
  • The first human study for a hormone-free male birth control pill is a long-awaited milestone and a landmark achievement in the quest for reproductive autonomy.

The 'weird' male Y chromosome has finally been fully sequenced. Can we now understand how it works, and how it evolved?

Retrieved on: 
Thursday, August 24, 2023

It’s also small and seriously weird; it carries few genes and is full of junk DNA that makes it horrendous to sequence.

Key Points: 
  • It’s also small and seriously weird; it carries few genes and is full of junk DNA that makes it horrendous to sequence.
  • However, new “long-read” sequencing techniques have finally provided a reliable sequence from one end of the Y to the other.

Making baby boys

    • The embryonic testes make male hormones, and these hormones direct the development of male features in a baby boy.
    • Female hormones then direct the development of female features in the baby girl.

A DNA junkyard

    • It is smaller and bears few genes (only 27 compared to about 1,000 on the X).
    • The Y also has a lot of DNA sequences that don’t seem to contribute to traits.
    • This last DNA class occupies big chunks of the Y that literally glow in the dark; you can see it down the microscope because it preferentially binds fluorescent dyes.

Why the Y is weird

    • We have a lot of evidence that 150 million years ago the X and Y were just a pair of ordinary chromosomes (they still are in birds and platypuses).
    • Then SRY evolved (from an ancient gene with another function) on one of these two chromosomes, defining a new proto-Y.
    • Read more:
      Men are slowly losing their Y chromosome, but a new sex gene discovery in spiny rats brings hope for humanity

Sequencing Y was a nightmare

    • They’ve done this using short-read sequencing, which involves chopping the DNA into little bits of a hundred or so bases and reassembling them like a jigsaw.
    • But it’s only recently that new technology has allowed sequencing of bases along individual long DNA molecules, producing long-reads of thousands of bases.

So what’s new on the Y?

    • A few new genes have been discovered, but these are extra copies of genes that were already known to exist in multiple copies.
    • The border of the pseudoautosomal region (which is shared with the X) has been pushed a bit further toward the tip of the Y chromosome.
    • But perhaps the most important outcome is how useful the findings will be for scientists all over the world.

Male fertility crisis: what environmental contaminants have got to do with it

Retrieved on: 
Wednesday, July 19, 2023

For many years people tended to blame women for a couple’s infertility – especially in African countries.

Key Points: 
  • For many years people tended to blame women for a couple’s infertility – especially in African countries.
  • And men worldwide – Africa included – are experiencing a worrying trend of decreased sperm count and quality.
  • However, it is clear that environmental contaminants play a large part in declining fertility worldwide.
  • Other contaminants that are increasing in prevalence and show signs of entering our food chain are pesticides and medication.

Impact on male fertility

    • The axis is the part of the endocrine system that controls reproductive functions – the ability to produce sperm in men and eggs in women.
    • We report that contaminants of emerging concern can also act directly on testicles by disrupting the blood-testis barrier.
    • This physical barrier protects the developing sperm from harmful substances that may be present in the bloodstream.

The legacy of fathers

    • But these epigenetic marks can affect how the genes within sperm work without changing the underlying DNA sequence.
    • Yet, these changes can be passed down from a parent to their child.
    • In both cases, epigenetic changes can be passed on to future generations who have not been directly exposed to the contaminants.
    • One category of compounds whose impact on epigenetic marks that has been extensively studied is nonsteroidal anti-inflammatory drugs such as paracetamol and ibuprofen.

Taking charge

    • But it’s not easy to detect and eradicate these contaminants.
    • Current control measures include regulatory frameworks to limit the use of certain pesticides or pharmaceuticals, and develop safer alternatives.

Male fertility crisis – what environmental contaminants have got to do with it

Retrieved on: 
Wednesday, July 19, 2023

And men worldwide – Africa included – are experiencing a worrying trend of decreased sperm count and quality.

Key Points: 
  • And men worldwide – Africa included – are experiencing a worrying trend of decreased sperm count and quality.
  • However, it is clear that environmental contaminants play a large part in declining fertility worldwide.
  • Other contaminants that are increasing in prevalence and show signs of entering our food chain are pesticides and medication.
  • Our study suggests that these “contaminants of emerging concern” might be contributing to the male infertility crisis in surprising ways.

Impact on male fertility

    • The axis is the part of the endocrine system that controls reproductive functions – the ability to produce sperm in men and eggs in women.
    • We report that contaminants of emerging concern can also act directly on testicles by disrupting the blood-testis barrier.
    • This physical barrier protects the developing sperm from harmful substances that may be present in the bloodstream.

The legacy of fathers

    • But these epigenetic marks can affect how the genes within sperm work without changing the underlying DNA sequence.
    • Yet, these changes can be passed down from a parent to their child.
    • In both cases, epigenetic changes can be passed on to future generations who have not been directly exposed to the contaminants.
    • One category of compounds whose impact on epigenetic marks that has been extensively studied is nonsteroidal anti-inflammatory drugs such as paracetamol and ibuprofen.

Taking charge

    • But it’s not easy to detect and eradicate these contaminants.
    • Current control measures include regulatory frameworks to limit the use of certain pesticides or pharmaceuticals, and develop safer alternatives.

Male fertility crisis - what environmental contaminants have got to do with it

Retrieved on: 
Tuesday, July 18, 2023

And men worldwide – Africa included – are experiencing a worrying trend of decreased sperm count and quality.

Key Points: 
  • And men worldwide – Africa included – are experiencing a worrying trend of decreased sperm count and quality.
  • However, it is clear that environmental contaminants play a large part in declining fertility worldwide.
  • Other contaminants that are increasing in prevalence and show signs of entering our food chain are pesticides and medication.
  • Our study suggests that these “contaminants of emerging concern” might be contributing to the male infertility crisis in surprising ways.

Impact on male fertility

    • The axis is the part of the endocrine system that controls reproductive functions – the ability to produce sperm in men and eggs in women.
    • We report that contaminants of emerging concern can also act directly on testicles by disrupting the blood-testis barrier.
    • This physical barrier protects the developing sperm from harmful substances that may be present in the bloodstream.

The legacy of fathers

    • But these epigenetic marks can affect how the genes within sperm work without changing the underlying DNA sequence.
    • Yet, these changes can be passed down from a parent to their child.
    • In both cases, epigenetic changes can be passed on to future generations who have not been directly exposed to the contaminants.
    • One category of compounds whose impact on epigenetic marks that has been extensively studied is nonsteroidal anti-inflammatory drugs such as paracetamol and ibuprofen.

Taking charge

    • But it’s not easy to detect and eradicate these contaminants.
    • Current control measures include regulatory frameworks to limit the use of certain pesticides or pharmaceuticals, and develop safer alternatives.

Testicular Cancer - Global Pipeline Insights, 2022: Featuring Sanofi, Seagen, BioNTech, Context Therapeutics & Leadartis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape.

Key Points: 
  • This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape.
  • Testicular cancer is one of the most common malignancies in men aged 15 to 45 years.
  • Complex environmental and genetic factors are involved in the development of testicular cancer; common risk factors include cryptorchidism, family history of testicular cancer, personal history of testicular cancer in the contralateral testis, age, and ethnicity.
  • Testicular Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

Retrieved on: 
Thursday, October 20, 2022

We are excited to bring our first MyT Platform derived product candidate into the clinic, added Thomas M. Soloway, Chief Executive Officer of T-knife.

Key Points: 
  • We are excited to bring our first MyT Platform derived product candidate into the clinic, added Thomas M. Soloway, Chief Executive Officer of T-knife.
  • The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial designed to evaluate the safety and preliminary efficacy of TK-8001 in patients with MAGE-A1 positive solid tumors.
  • The Phase 1 part of the study is focused on the selection of a dose to advance into the Phase 2 part of the study.
  • Once the recommended Phase 2 dose has been identified, TK-8001 will then be evaluated in an expansion part of the trial.

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies Bundle Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022

The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.
  • This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.
  • The tetraspan membrane protein is a member of the claudin family of tight junction proteins.
  • The transmembrane protein CLDN6 is virtually absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need.

2022 GPRC5D-Targeted Therapy Report - Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 19, 2022

The "GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The report has identified the players in the field and presents a competitive landscape analysis of stakeholders and a pipeline review based on the specific profiles of drug candidates and companies active in the field.
  • The report includes information about business transactions in the field, such as acquisitions, partnerships & collaborations and licensing deals.
  • GPRC5D expression on CD138 cells is independent of B-cell maturation antigen (BCMA) expression and showed a membranous pattern.